Table 3:
Survival analysis by Cox regression (univariate analysis) of parameters that influence overall survival in FIGO IB substages
| StageIB1 | Stage 1B2 | Stage 1B3 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | Overall survival HR |
95% CI | p | Overall survival HR |
95% CI | p | Overall survival HR |
95% CI | p |
| Age | 1.11 | 0.23-5.26 | 0.88 | 1.51 | 0.41-5.51 | 0.52 | 1.61 | 0.34-7.53 | 0.54 |
| Surgical treatment | 1.48 | 0.72-3.02 | 0.27 | 9.70 | 0.01-999.99 | 0.53 | 4.56 | 0.01-999.99 | 0.85 |
| HPV status | 4.67 | 0.94-23.25 | 0.05 | 1.99 | 0.52-7.53 | 0.30 | 2.42 | 0.47-12.35 | 0.28 |
| Silva pattern | 2.25 | 0.63-8.10 | 0.21 | 3.10 | 0.56-16.95 | 0.19 | 10.87 | 0.002-74039.22 | 0.59 |
| Histologic grade | 2.64 | 0.92-7.56 | 0.06 | 1.18 | 0.45-3.07 | 0.73 | 2.51 | 0.71-8.92 | 0.15 |
| Lymph-vascular invasion |
3.24 | 0.77-13.62 | 0.10 | 2.68 | 0.82-8.76 | 0.10 | 2.10 | 0.25-17.67 | 0.49 |
| Precursor lesions | 2.26 | 0.50-10.10 | 0.28 | 1.60 | 0.46-5.55 | 0.45 | 1.70 | 0.28-10.37 | 0.56 |
| Lymph node metastases | 6.05 | 1.51-24.25 | 0.011 | 2.43 | 0.64-9.19 | 0.18 | 7.77 | 0.70-86.02 | 0.09 |
FIGO, International Federation of Gynecology and Obstetrics; HPV, human papillomavirus